ADVB Advanced Biomed Inc.
AI brief AI-written, not reviewed by a person
The latest 12-month period ending 2026-06-30 shows a diluted EPS of 5.33 USD and net income of 6,677,077 USD, with stockholders’ equity of 12,276,727 USD and revenue of 127,637 USD for that year; by comparison, the prior year (12 months to 2025-06-30) posted a diluted EPS of -3.18 USD and net income of -3,258,969 USD, with stockholders’ equity of 9,209,737 USD and revenue of 0.00 USD for that year, highlighting a substantial year-over-year swing in profitability while balance sheet totals trended higher in 2026.
- 12 months to 2026-06-30 diluted EPS: 5.33 USD per share, vs 12 months to 2025-06-30: -3.18 USD per share. [1]
- 12 months to 2026-06-30 net income: 6,677,077 USD, vs 12 months to 2025-06-30: -3,258,969 USD. [1]
- Stockholders' equity at 2026-06-30: 12,276,727 USD; at 2025-06-30: 3,477,564 USD (also shown 2025-12-31: 9,481,642 USD; 2025-09-30: 3,004,124 USD; 2025-06-30: 3,477,564 USD). [1]
- Revenue (year) 12 months to 2026-06-30: 127,637 USD; for 12 months to 2025-06-30: 0 USD (implied from table). [1]
- Total assets at 2026-06-30: 13,750,716 USD; at 2026-03-31: 10,646,324 USD; prior periods show 2025-12-31: 10,850,712 USD. [1]
- Total liabilities at 2026-06-30: 1,473,989 USD; at 2026-03-31: 1,436,587 USD; 2025-06-30: 19,384,531 USD (note: appears as a high value in 2025-06-30 entry). [1]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Revenue (year) (12 months to 2026-06-30) | 127,637 USD | sec-companyfacts | current | ||
| Net income (quarter) (3 months to 2026-03-31) | -488,942 USD | sec-companyfacts | current | ||
| Net income (year) (12 months to 2026-06-30) | 6,677,077 USD | sec-companyfacts | current | ||
| Operating income (year) (12 months to 2026-06-30) | -6,233,542 USD | sec-companyfacts | current | ||
| Diluted EPS (quarter) (3 months to 2026-03-31) | -0.38 USD/shares | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2026-06-30) | 5.33 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (quarter) (3 months to 2025-09-30) | -610,342 USD | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2026-06-30) | -1,946,943 USD | sec-companyfacts | current | ||
| Total assets (at 2026-06-30) | 13,750,716 USD | sec-companyfacts | current | ||
| Total liabilities (at 2026-06-30) | 1,473,989 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-06-30) | 12,276,727 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-10-13) | 1,652,133 shares | sec-companyfacts | current |
Context
No reviewed context has been published for ADVB. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add ADVB to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: ADVB.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.